HBV Journal Review[Nov]Adefovir-Telbivudine Combination Effective in Lamivudine-

StephenW

Adefovir-Telbivudine Combination Effective in  Lamivudine-Resistant Patients                  

                  With several antivirals now available, researchers  are trying to determine which combination will be most effective in patients.  Each antiviral targets a different region of the virus, and combinations may be  especially effective in people who have developed resistance to some  antivirals, such as lamivudine (Epivir-HBV), which has a high rate of  resistance.
                  In a recent study reported in the journal Hepatology International, researchers studied the effectiveness of the  antiviral adefovir (Hepsera) used alone or in combination with telbivudine  (Tyzeka) over 48 weeks  in patients who  had developed resistance to lamivudine.
                  Declines in HBV DNA were greater in the group  received the antiviral combination (viral load drops were 7.4-fold in the  combination group, compared with 4.9-fold in the group treated with only  adefovir.) Additionally, 38.5% of the group receiving both antivirals achieved  undetectable HBV DNA compared to the group treat with only adefovir.
                  Two adefovir-only patients developed a viral  breakthrough due to the drug’s ineffectiveness. None of the combination-treated  patients experienced a resurgence of viral load.
                  HBeAg loss occurred in 3 patients in the combination  group and one patient in the adefovir group.

StephenW

阿德福韦，替比夫定拉米夫定耐药的患者有效组合

现已几种抗病毒药物，研究人员正试图确定该组合将患者最有效的。每个抗病毒药物的目标不同地区的病毒，和组合可能是谁开发的耐一些抗病毒药物，如拉米夫定（Epivir- HBV），其中具有高电阻率的人特别有效。

在最近的一项研究在国际肝病杂志报道，研究人员研究的抗病毒药物阿德福韦（Hepsera）单独或联合使用替比夫定（TYZEKA）已发展到拉米夫定耐药的患者超过48周的有效性。

组中的HBV DNA下降更大的抗病毒药物组合（病毒载量下降，联合组的7.4倍，比只有阿德福韦治疗组的4.9倍。）此外，本集团的38.5％，同时接受抗病毒药物实现检测不到乙肝病毒DNA相比，只有阿德福韦组治疗。

只有两个阿德福韦患者开发的一种病毒性的突破，由于药物的无效。组合治疗的患者都没有经历过的病毒载量的复苏。

HBeAg消失，3例发生在阿德福韦group.report在巴尔的摩医学杂志“10月号发表的联合组和一个病人。